The origin of indoleacetic acid and indolepropionic acid in rat and human cerebrospinal fluid

Abstract: Using a new high performance liquid chromatographic method we have measured tryptophan, 5-hydroxyindoleacetic acid (5HIAA), indoleacetic acid (IAA), and indolepropionic acid (IPA) in rat and human CSF. Experiments on rats indicate that IPA in CSF is not derived from the CNS but from bacterial metabolism in the intestine. However, IAA in CSF is derived from CNS tryptamine metabolism. Some tryptamine that is formed peripherally diffuses across the blood-brain barrier and augments the tryptamine formed within the CNS. We have concluded from our data that (i) measurements on CSF are a useful way of studying trace amine metabolism in human CNS, but it is essential to establish the anatomical and metabolic origin of any metabolite found in the CSF; and (ii) tryptamine metabolism is more important in man than in the rat.     

Effect of psychotropic drugs on 3,4-dihydroxyphenylacetic acid (DOPAC) content in the medial basal hypothalamus

The effect of different psychotropic drugs on 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the medial basal hypothalamus has been studied by the use of a very sensitive radioenzymatic method. Apomorphine and haloperidol, which are known to respectively decrease and increase DOPAC levels in the caudate nucleus, fail to influence DOPAC level in the medial basal hypothalamus. Reserpine, which increases DOPAC level in the caudate nucleus, decreases it in the medial basal hypothalamus. Amphetamine decreases DOPAC level in the medial basal hypothalamus as it does in the caudate nucleus. These results suggest that DA metabolism in the medial basal hypothalamus is controlled by mechanisms different from those operating in other brain areas.     

Selected ion monitoring assay for biogenic amine metabolites and probenecid in human lumbar cerebrospinal fluid

Details are presented of an improved selected ion monitoring assay for the major biogenic amine metabolites and probenecid in human lumbar cerebrospinal fluid (CSF). The metabolites and probenecid are simultaneously extracted with ethyl acetate from an acidified aqueous phase, and are simultaneously converted to pentafluoropropionyl esters by reaction with pentafluoropropionic anhydride and pentafluoropropanol. The esters of the metabolites are analyzed following a single injection of the derivatized sample onto the gas chromatographic column, while the ester of probenecid is analyzed following a separate injection onto the gas chromatographic column. Quantitation is achieved using for internal standards deuterated analogues of the metabolites and a chemical analogue of probenecid. Data are presented on the concentration of free and conjugated forms of the metabolites in lumbar CSF taken from healthy volunteers.     

Regional distribution of the histamine metabolite, tele-methylimidazoleacetic acid, in rat brain: effects of pargyline and probenecid

Abstract: tele -Methylimidazoleacetic acid (t-MIAA), a major brain histamine metabolite, was measured in nine rat brain regions by a gas chromatography-mass spectrometric method that also measures the precursor amine, tele -methylhistamine (t-MH). The t-MIAA concentration of cerebellum, medulla-pons, midbrain, caudate nucleus, hypothalamus, frontal cortex, hippocampus, and thalamus varied 15-fold, hypothalamus showing the highest level (2.21 nmol/g) and cerebellum the lowest (0.15 nmol/ g). The concentrations of t-MIAA and t-MH were significantly correlated in all regions except midbrain, which had relatively more t-MIAA. Probenecid did not alter whole-brain t-MIAA levels. Treatment with pargyline, an inhibitor of monoamine oxidase, lowered the t-MIAA levels in all regions.     

Effect of probenecid on 5-hydroxyindoleacetic acid in cisternal cerebrospinal fluid of rats with portacaval anastomosis

Portal-systemic encephalopathy (PSE) is characterized by a neuropsychiatric disorder progressing through personality changes, to stupor and coma. Previous studies have revealed alterations of serotonin and of its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in brain tissue and CSF in experimental (rat) and human PSE. Increased brain 5-HIAA concentrations could result from its decreased removal rather than to increased serotonin metabolism. In order to evaluate this possibility, CSF 5-HIAA concentrations were measured using an indwelling cisterna magna catheter technique at various times following end-to-side portacaval anastomosis in rats (the most widely used animal model of PSE) treated with probenecid, a competitive inhibitor that blocks the active transport of acid metabolites out of the brain and CSF. Following portacaval anastomosis and probenecid treatment, CSF concentrations of 5-HIAA were increased to a greater extent than in sham-operated controls. When data were expressed as per-cent baseline values, the relative increase of CSF 5-HIAA in portacaval shunted rats following probenecid treatment was not significantly different from sham-operated controls. These findings confirm that increased 5-HIAA in the CNS in experimental PSE results from increased 5HT metabolism or turnover and that the probenecid-sensitive acid metabolite carrier is intact in PSE.     

Contribution of plasma homovanillic acid (HVA) to urine and cerebrospinal fluid HVA in the monkey and its pharmacokinetic disposition.

Homovanillic acid (HVA) labelled with two deuterium atoms (d₂-HVA) was used to determine the contribution of HVA in the blood to HVA in the urine and CSF of monkeys. During and after a six-hour intravenous infusion of d₂-HVA at a constant rate, the levels of both d₂-HVA and endogenous HVA (d₀-HVA) in plasma, urine, and CSF were determined by gas chromatography-mass spectrometry, and the relative enrichments of d₂-HVA in each of these fluids calculated. Results indicate that HVA in the urine is derived exclusively from the blood, with no contribution from renal metabolism of dopamine (DA). Furthermore, less than one percent of HVA in either lumbar or ventricular CSF is derived from circulating HVA. The plasma elimination curve of d₂-HVA was biexponential, with a terminal phase half-life ($\text{t}{}_{\mathrm{<mtext>1</mtext><mtext>2</mtext>}}$) of 44 minutes and an apparent volume of distribution of 0.8 liters/kg.     

Release of neuron specific enolase (NSE) in cerebrospinal fluid following experimental lesions of the rat brain

Neuron-specific enolase (NSE) levels were measured by sandwich enzymo-immunoassay as well as by enzymatic assay in rat cerebrospinal fluid (CSF), following mechanical lesions of the brain tissue. Significant increases of NSE were observed in CSF, with a peak 2 h following lesions located near the lateral ventricle. Values returned to normal around 48 h later. In another experimental group, lesions were realized further away from the lateral ventricle; the elevation of NSE in CSF reached the maximal value 11 h later. In addition, measurements which were performed following lesions at the same location but of various sizes, indicated that the quantity of NSE released is proportional to the extent of brain damage. The possible factors which govern the time course and amount of NSE release in CSF are discussed. These results suggest that NSE could be a useful and easily detected marker of neuronal damage.     

The effect of probenecid on catecholamine metabolites in human cerebrospinal fluid analyzed by mass fragmentography.

A gas chromatography-mass fragmentography (GC-MS) method was used to measure homovanillic acid (HVA), vanillylmandelic acid (VMA) and 3-methoxy-4-hydroxyphenethylene glycol (MHPG) in lumbar cerebrospinal fluid (CSF) of 31 patients before and after treatment with probenecid. HVA values increased from 24.6 ± 2.6 S.E.M. to 210 ± 17 ng/ml. The increase in VMA was from 1.06 ± 0.23 to 2.22 ± 0.17 ng/ml and that of MHPG was from 12.2 ± 1.08 to 15.6 ± 1.27 ng/ml. All increases were significant (p = < .01). The results for MHPG and HVA are consistent with results of earlier studies using different methods. VMA concentrations increased significantly but at a rate much lower than those of HVA.     

Amperometric biosensor based on tyrosinase-conjugated polysaccharide hybrid film: selective determination of nanomolar neurotransmitters metabolite of 3,4-dihydroxyphenylacetic acid (DOPAC) in biological fluid

The amperometric detection of neurotransmitters metabolite of 3,4-dihydroxyphenylacetic acid (DOPAC) was achieved at a tyrosinase-chitosan composite film-modified glassy carbon (GC) electrode. The optimal conditions for the preparation of the biosensor were established. This bio-composite film was characterized by scanning electron microscopy (SEM) and Fourier transformed infrared (FT-IR) spectra, suggesting that chitosan covalently connected to chitosan chains. Electrochemical characterization of the bio-hybrid membrane-covered electrodes were also performed in 0.05 M phosphate buffer solution (pH 6.52) containing neurotransmitters or their derivatives by using cyclic voltammetry (CV), linear sweep voltammetry (LSV), square wave voltammetry (SWV) and amperometry. This simply-prepared protein-polysaccharide hybrid film provides a microenvironment friendly for enzyme loading. The sensor was operated at -0.15 V with a short response time. The current linearly increased with the increasing concentration of DOPAC over the concentration of 6 nM-0.2 mM. The lower detection limit for DOPAC is 3 nM (S/N=3). The sensitivity of the sensor is 40 microA mM(-1). A physiological level of neurotransmitters and their derivatives including dopamine, l-dopa, adrenaline, noradrenaline and homovanillic acid as well as ascorbic acid, uric acid and acetaminophen do not affect the determination of DOPAC.     

Transport of alovudine (3'-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis

Extracellular unbound concentrations of alovudine were sampled by microdialysis in order to study the transport of alovudine between the blood and the brain and the cerebrospinal fluid (CSF) in the rat. The AUC (area under the curve) ratio CSF/blood was higher than the brain/blood ratio after i.v. infusion of alovudine 25mg/kg/hr after a loading dose of 25 mg/kg in 5 minutes (n=4). Neither i.v. infusion of thymidine (25 mg/kg/hr, n=5; 100 mg/kg/hr, n=2) nor acetazolamide (50 mg/kg i.p. bolus followed by 25 mg/kg i.p. every second hour, n=3) influenced the brain/blood AUC ratio after alovudine 25 mg/kg s.c. injection compared to controls (n=5). Finally, perfusion through the microdialysis probe with thymidine (1000 microM, n=3) had also no effect on the brain/blood AUC ratio after alovudine 25 mg/kg s.c. Because neither thymidine nor acetazolamide has significant influence on the ability of alovudine to penetrate the blood-brain barrier in the rat, neither thymidine transport nor carboanhydrase dependent CSF production appear to be major determinants of the blood-brain concentration gradient. Thus, it is concluded that alovudine reaches the extracellular fluid of the brain not by cerebrospinal fluid, but via the cerebral capillaries and that the existence of a concentration gradient over both blood-brain and CSF-brain barrier can probably be explained by the presence of an active process pumping alovudine out from the brain.